VERSARTIS
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The compan... y is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.
VERSARTIS
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2008-12-01
Address:
Menlo Park, California, United States
Country:
United States
Website Url:
http://www.versartis.co
Total Employee:
11+
Status:
Closed
Contact:
16509638598
Email Addresses:
[email protected]
Total Funding:
144.5 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail IPv6 Microsoft Azure DNS GoDaddy DNS Microsoft Unified Layer Comcast Akamai Hosted
Similar Organizations
ORGANIC GENOMICS
ORGANIC GENOMICS is a biotechnology company for developing health care products of therapeutic proteins.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
New Leaf Venture Partners
New Leaf Venture Partners investment in Series E - Versartis
Aisling Capital
Aisling Capital investment in Series E - Versartis
Advent Life Sciences
Advent Life Sciences investment in Series E - Versartis
Sofinnova Investments
Sofinnova Investments investment in Series E - Versartis
Amunix
Amunix investment in Series D - Versartis
New Leaf Venture Partners
New Leaf Venture Partners investment in Series D - Versartis
Sofinnova Investments
Sofinnova Investments investment in Series D - Versartis
Aisling Capital
Aisling Capital investment in Series D - Versartis
Advent Venture Partners
Advent Venture Partners investment in Series D - Versartis
Index Ventures
Index Ventures investment in Series D - Versartis
Official Site Inspections
http://www.versartis.co
- Host name: box2407.bluehost.com
- IP address: 50.87.227.169
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
More informations about "Versartis" on Search Engine
Versartis - Crunchbase Company Profile & Funding
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life …See details»
Versartis Company Profile 2024: Valuation, Investors, Acquisition ...
Versartis is headquartered in Menlo Park, CA. What is the size of Versartis? Versartis has 27 total employees. What industry is Versartis in? Versartis’s primary industry is Drug …See details»
Versartis Enters into Merger Agreement with Aravive
Jun 4, 2018 MENLO PARK, Calif. and HOUSTON, June 04, 2018 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), and Aravive Biologics, Inc., today jointly announced …See details»
Versartis grabs $126M in an upsized IPO to fund its orphan drug
Mar 21, 2014 A month removed from raising $55 million in Series E cash, Versartis ($VSAR) has hauled in $126 million more in an IPO, filling its coffers and planning to take …See details»
Aravive Biologics and Versartis complete merger - Seeking Alpha
Oct 15, 2018 Aravive Biologics, and Versartis ( NASDAQ: VSAR-OLD) closes its merger following Versartis stockholder approval on October 5. Beginning October 16, the …See details»
Versartis Inc | LinkedIn
Versartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, …See details»
Versartis stock climbs on reverse merger with Aravive
Jun 5, 2018 Aravive and Versartis Biologics have signed a definitive agreement to merge the clinical-stage oncology biopharma with a wholly-owned Versartis subsidiary in an all …See details»
Versartis - Funding, Financials, Valuation & Investors - Crunchbase
Versartis has raised a total of. $279.5M. in funding over 8 rounds. Their latest funding was raised on Sep 27, 2016 from a Post-IPO Equity round. Versartis is registered under the …See details»
Versartis, Inc. (VSAR) Company Profile & Facts - Yahoo Finance
See the company profile for Versartis, Inc. (VSAR) including business summary, industry/sector information, number of employees, business summary, corporate …See details»
Versartis - Contacts, Employees, Board Members, Advisors
Organization. Versartis. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Employee Profiles 4. Number of Board Member …See details»
Behind the Brand with Versartis - YouTube
Sep 20, 2023 Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing novel, long-acting recombinant human growth hormone for the treatment ...See details»
Versartis: High Investment Potential Addressing Unmet Need
Oct 17, 2016 2.03K Follower s. Summary. Versartis is developing somavartan, a long-acting recombinant human growth hormone, for treating pediatric and adult Growth …See details»
Versartis, Inc. Appoints Jay Shepard As President And CEO
May 7, 2015 MENLO PARK, Calif., May 6, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing …See details»
Versartis, Inc. (VSAR) - Yahoo Finance Canada
Profile. Holdings. Performance. Risk. Purchase info. Sustainability. 1m. YTD. 1y. 5y. Max. Full screen. Find the latest Versartis, Inc. (VSAR) stock quote, history, news and other …See details»
Versartis: Could This Be A Successful Turnaround In The Making?
Jun 15, 2018 Summary. Despite our robust returns since inception, we have some bad calls as anticipated. And Versartis was one of them. Phase 3 (VELOCITY) trial did not …See details»
Versartis, Inc. (VSAR) Stock Price, News, Quote & History
Zacks 17 days ago. The Surprising Top Mutual Fund in the First Quarter. The Wall Street Journal last month. Are these 3 Top-Ranked Mutual Funds In Your Retirement Portfolio? …See details»
Versartis Closes $20 Million Series D Venture Financing - Yahoo …
Oct 8, 2013 REDWOOD CITY, CA-- (Marketwired - Oct 8, 2013) - Versartis, Inc., an emerging biotechnology company developing novel therapeutics for patients with …See details»
Versartis, Inc. Completes Series A Funding of $11 Million [EUR …
Jun 2, 2009 Versartis, Inc., a biotechnology company headquartered in Redwood City, California, is developing therapeutic proteins for the treatment of metabolic diseases and …See details»
Versartis Enters into Merger Agreement with Aravive Biologics to …
Jun 4, 2018 MENLO PARK, Calif. and HOUSTON, June 04, 2018 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), and Aravive Biologics, Inc., today jointly announced …See details»
Working At Versartis: Employee Reviews And Culture - Zippia
Mar 16, 2023 Organization Type. Public. CEO. Jay Shepard. Versartis, Inc. is a biotechnology company developing therapeutic proteins for the treatment of endocrine …See details»